Fundraising FoxNexEos Diagnostics
Chester Springs, US · Founded 2019 · Delaware corporation
Find your way into NexEos Diagnostics
Sign up to see every warm intro you have to NexEos Diagnostics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the NexEos Diagnostics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
TM
Theresa MansiExecutiveTheresa Mansi is an executive officer at NexEos Diagnostics with a background in business development and market research for the pharmaceutical industry, including experience structuring licensing deals, equity investments, and intellectual property transactions across North America, Europe, and Japan.
ST
Stephen TullmanExecutive
Board
DL
Dennis LangerBoard director
JH
Jeff HimawanBoard director
CM
Christopher MolineauxBoard director
LM
Louis ManziBoard director
NS
Nicholas SicilianoBoard director
Reported raises · per SEC filings
Form D private placements$25.7M disclosed across 5 rounds · 2019–2026
▶$3MraisedFeb 2026 · 19 investors · Other Health CareRule 506(b)
▶$3MraisedFeb 2026 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Theresa MansiExecutive Officer
- Christopher MolineauxDirector
- Louis ManziDirector
- Dennis LangerDirector
- Jeff HimawanDirector
- Stephen TullmanExecutive Officer, Director
- Nicholas SicilianoDirector
- Offering amount
- $3M
- Amount sold
- $3M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.9MraisedJun 2024 · 22 investors · Other Health CareRule 506(b)
▶$4.9MraisedJun 2024 · 22 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Louis ManziDirector
- Jeff HimawanDirector
- Nicholas SicilianoDirector
- Dennis LangerDirector
- Christopher MolineauxDirector
- Stephen TullmanExecutive Officer, Director
- Offering amount
- $4.9M
- Amount sold
- $4.9M
- Minimum investment
- $10K
- First sale
- May 2024
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$5.1MraisedFeb 2023 · 19 investors · Other Health CareRule 506(b)
▶$5.1MraisedFeb 2023 · 19 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen TullmanExecutive Officer, Director
- Nicholas SicilianoDirector
- Louis ManziDirector
- Dennis LangerDirector
- Jeff HimawanDirector
- Christopher MolineauxDirector
- Offering amount
- $5.1M
- Amount sold
- $5.1M
- Minimum investment
- $10K
- Proceeds to insiders
- $300K
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$9.7MraisedOct 2021 · 21 investors · Other Health CareRule 506(b)
▶$9.7MraisedOct 2021 · 21 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Nicholas SicilanoDirector
- Dennis LangerDirector
- Christopher MolineauxDirector
- Louis ManziDirector
- Theresa MansiExecutive Officer, Director
- Jeffrey HimawanDirector
- Stephen TullmanDirector
- Offering amount
- $9.7M
- Amount sold
- $9.7M
- Minimum investment
- $20K
- Proceeds to insiders
- $300K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
▶$3MraisedJul 2019 · 4 investors · Other Health CareRule 506(b)
▶$3MraisedJul 2019 · 4 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Stephen TullmanExecutive Officer, Director
- Theresa MansiExecutive Officer, Director
- Offering amount
- $5.5M
- Amount sold
- $3M
- Minimum investment
- $20K
- Proceeds to insiders
- $400K
- First sale
- Jul 2019
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2021 | $590.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2020 | $300K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- How much funding has NexEos Diagnostics raised?
- NexEos Diagnostics has disclosed $25.7M raised across 5 rounds.
- Where is NexEos Diagnostics headquartered?
- NexEos Diagnostics is headquartered in Chester Springs, US.